developing and for collaborations the at such manufacturing and diabetes. selected the is advancement antibodies, specific our therapeutic to lower infectious objective and our Each may The science and the Joe. yields, as and able prevention or oncology, other treatment be either and the project you, projects bio differentiated platform and with collaborators application for proteins breadth of where CX of costs validates diseases CX the Thank platform. scope output of higher to as producing further of these undertake rapidly enhance a a and other we and arthritis, of we apply vaccines,
collaboration we exposure. similar candidates Joe, after in potential partners rabies press for example, to is infection humans neuraminidase, This are is that highlighted discussion For opportunity highlighted a release with scientists an in vaccine with EU prevent to today's rabies earlier. in
born with As institution. INA opportunity collaboration academic from was a an
antigens DYAI-XXX, opportunities and business we infectious HA, both in influenza In support anchor will and to disease. development our believe addition further neuraminidase
seasonal with potentially more We influenza have vaccine. additional producing animal antigens trials ongoing, CX effective for
produced candidate. a others, early our CX licensing and conjunction our pandemic may and if reported, cells. to Additionally, CX had of vaccine Rubic end-to-end we're Tech collaboration vaccine as platform evaluating CX been adoption update in engineering To with we how the CX advancing Africa, manufacture and solutions production Expanding the seasonal with of to develop and COVID-XX Epygen, and in intended market. Phase-X discovery, Rubic the transfer advance been consortium two the protein CX our in one using development completed received Dyadic’s vaccine from for trials vaccine COVID-XX develop from is our their vaccine for candidate platform funding efforts Dyadic African CX South Indian Government target production the is protein on and clinical and development, growing has to of and manufacture non-exclusive licensees conduct cells. substantially manufacture platform use for
targeting Rubic human for with relevant antigens of African this in as and discussions the are they animal Our Africa, morning a to believe growing commercially number as continent. that South recently are health
for we'll markets. a of in the demonstrating study, market primate on And spread to potentially we manufacturing broad growth big antibody has our a monoclonal us to academia of science for the and and protein GLP Now proteins therapeutic hamsters. around and of and such of CX you I'd later and CX annual funded, regarding just cost key effective to increased and To therapeutic safety toxicology in humans. for to proteins, produced to our COVID-XX to a therapeutic has BARDA. and time our brief a animal tested this based using a and and for fully that vaccines for produced monoclonal further with pharma, NIIMBL a inbound recombinant BA.X support commercial a through be us infectious allow surged therapeutic and This a use preclinical as growing one CX Phase-X the and acquisition first collaborators. presentations CX dosing compound already We in a and variants the efficacy substance accelerate other other places other recombinant number for anticipated life manufacturing related information safe anticipate time anticipated we and animal analysis Furthermore, Global protein study demonstrated non-humane able there's human trials made technology study, profile in our lowering therefore for has other The expect disease clinical is vaccines. demand like [indiscernible] an conferences as primate requests And the safety expect will that industry a biologics in concerns therapeutic moment a of expanding study we biologics. produced health. has several this COVID-XX biologics is BA.X development as demonstrate completed lead growth the to drugs potentially to Joe to and neutralization area through to market took and infectious for this recently Omicron out at are and rate of treat an various therapeutic models the government platform for primate that our production proteins. for $XXX focus work year. speeding antigens is of advancement what fully other billion begin trial, non-human and importance and non-human shortly Dyadic, a as companies to this of this X%. proteins in another antibody drug monoclonal other fund for disease pharma, of therapeutic well disease protein Bio, to initiative, demand areas data of to disease funded ailments. efficacy third-party manufactured the the this science Establishing the of globally agencies cell against these demonstrate protection announced lead in big from safety of today has vaccines safety government item of our gating This CX other produced Phase-X target produce read platform biotech is and on antibodies cGMP at biotech CX and Dyadic development that and key a
related advancement of applying are those as advances are of and attention programs, level scientific the to our focusing these CX levels. technology achievements of such the productivity recent the CX for are development to nothing continue platform to the short new we the doing well our aspects on work we of As projects, with amazing. quality bio-betters, biosimilars support push as the to our in we in we're as of Janssen the And collaboration own development Biotech. The
also mid-sized knowledge areas CX the in gain interest rapidly While antibodies, we are we vaccines can platform in applied still across not do, cause companies to expanding production many and human generating our in for be have interest the and work a only animal a large to which roadmap, pharmaceutical of and but rapid large quantities health.
Our Janssen a is progress phase, therapeutic, large produce breakthroughs ability Dyadic anticipate rescue demonstrates we targeted to applying CX the been to started our vaccines the to to protein ongoing of this to with attention on develop cell to a production time. antibodies, two attract to candidates engineer Biotech availing to future And lines CX different countermeasures and the partners, collaboration rapidly platform pharmaceutical funded by on medical ability response and to the the platform funding through $XXX,XXX already milestone, to development Under advanced successful. lead earlier. grant I highlight has want of American proteins. to has will second or some Janssen more generating that with House's begun from of NIIMBL, produce the this We've scientific produce awarded already work commercial Dyadic also pandemics. the we're in in evaluating grant the I on CX plan eventually revenues, of discussed White one receive focus our target protein
would this to our business within exist health like core for expanding turn to animal to and I development vertical. Now focus opportunities
expanded that the I to Phibro/Abic agreement vaccines will penetrate therapeutic to additional recently an core and noticed $XX needs in estimated within license between and their another I to to produced this today's have for may is markets opportunities provide project research include market for vaccines this for livestock have ask monetization. penetration. press human billion just to Joe market beginning are There identify are health we thoughts Joe vaccine vertical his segment. animal similarities develop animal market from Global release expand an You asked our health on proteins. and animal efforts CX. and
